Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.

Ngo-Giang-Huong N, Wittkop L, Judd A, Reiss P, Goetghebuer T, Duiculescu D, Noguera-Julian A, Marczynska M, Giacquinto C, Ene L, Ramos JT, Cellerai C, Klimkait T, Brichard B, Valerius N, Sabin C, Teira R, Obel N, Stephan C, de Wit S, Thorne C, Gibb D, Schwimmer C, Campbell MA, Pillay D, Lallemant M; EuroCoord-CHAIN-EPPICC joint project study group.

BMC Infect Dis. 2016 Nov 8;16(1):654.

2.

Aviremia 10 Years Postdiscontinuation of Antiretroviral Therapy Initiated During Primary Human Immunodeficiency Virus-1 Infection and Association With Gag-Specific T-Cell Responses.

Kinloch-de Loes S, Dorrell L, Yang H, Hardy GA, Yerly S, Cellerai C, Vandekerckhove L, De Spielgelaere W, Malatinkova E, Wee Lee Koh W, Johnson MA.

Open Forum Infect Dis. 2015 Nov 23;2(4):ofv144. doi: 10.1093/ofid/ofv144. eCollection 2015 Dec.

3.

The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients.

Beerenwinkel N, Montazeri H, Schuhmacher H, Knupfer P, von Wyl V, Furrer H, Battegay M, Hirschel B, Cavassini M, Vernazza P, Bernasconi E, Yerly S, Böni J, Klimkait T, Cellerai C, Günthard HF; Swiss HIV Cohort Study.

PLoS Comput Biol. 2013;9(8):e1003203. doi: 10.1371/journal.pcbi.1003203. Epub 2013 Aug 29.

4.

Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells.

Viganò S, Bellutti Enders F, Miconnet I, Cellerai C, Savoye AL, Rozot V, Perreau M, Faouzi M, Ohmiti K, Cavassini M, Bart PA, Pantaleo G, Harari A.

PLoS Pathog. 2013;9(7):e1003423. doi: 10.1371/journal.ppat.1003423. Epub 2013 Jul 4.

5.

Multicenter evaluation of the Elecsys® anti-HCV II assay for the diagnosis of hepatitis C virus infection.

Esteban JI, van Helden J, Alborino F, Bürgisser P, Cellerai C, Pantaleo G, Eiras A, Rodriguez MI, Ghisetti V, Gleich M, Imdahl R, Kaiser C, Möller P, Wetlitzky O, Segovia M, Schennach H, Mühlbacher A.

J Med Virol. 2013 Aug;85(8):1362-8. doi: 10.1002/jmv.23536.

PMID:
23765774
6.

Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma.

Lange CM, Bibert S, Dufour JF, Cellerai C, Cerny A, Heim MH, Kaiser L, Malinverni R, Müllhaupt B, Negro F, Semela D, Moradpour D, Kutalik Z, Bochud PY; Swiss Hepatitis C Cohort Study Group.

J Hepatol. 2013 Sep;59(3):504-9. doi: 10.1016/j.jhep.2013.04.032. Epub 2013 May 9.

PMID:
23665287
7.

HIV testing practices by clinical service before and after revised testing guidelines in a Swiss University Hospital.

Darling KE, Hugli O, Mamin R, Cellerai C, Martenet S, Berney A, Peters S, Du Pasquier RA, Bodenmann P, Cavassini M.

PLoS One. 2012;7(6):e39299. doi: 10.1371/journal.pone.0039299. Epub 2012 Jun 28.

8.

Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients.

Scherrer AU, Ledergerber B, von Wyl V, Böni J, Yerly S, Klimkait T, Cellerai C, Furrer H, Calmy A, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Günthard HF; Swiss HIV Cohort Study.

PLoS One. 2012;7(6):e37983. doi: 10.1371/journal.pone.0037983. Epub 2012 Jun 18.

9.

Performance evaluation of a new fourth-generation HIV combination antigen-antibody assay.

Mühlbacher A, Schennach H, van Helden J, Hebell T, Pantaleo G, Bürgisser P, Cellerai C, Permpikul P, Rodriguez MI, Eiras A, Alborino F, Cunningham P, Axelsson M, Andersson S, Wetlitzky O, Kaiser C, Möller P, de Sousa G.

Med Microbiol Immunol. 2013 Feb;202(1):77-86. doi: 10.1007/s00430-012-0250-5. Epub 2012 Jun 17.

10.

Inferring epidemic contact structure from phylogenetic trees.

Leventhal GE, Kouyos R, Stadler T, Wyl Vv, Yerly S, Böni J, Cellerai C, Klimkait T, Günthard HF, Bonhoeffer S.

PLoS Comput Biol. 2012;8(3):e1002413. doi: 10.1371/journal.pcbi.1002413. Epub 2012 Mar 8.

11.

Assessing predicted HIV-1 replicative capacity in a clinical setting.

Kouyos RD, von Wyl V, Hinkley T, Petropoulos CJ, Haddad M, Whitcomb JM, Böni J, Yerly S, Cellerai C, Klimkait T, Günthard HF, Bonhoeffer S; Swiss HIV Cohort Study.

PLoS Pathog. 2011 Nov;7(11):e1002321. doi: 10.1371/journal.ppat.1002321. Epub 2011 Nov 3.

12.

Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations.

von Wyl V, Yerly S, Böni J, Shah C, Cellerai C, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Ledergerber B, Günthard HF; Swiss HIV Cohort Study.

Clin Infect Dis. 2012 Jan 1;54(1):131-40. doi: 10.1093/cid/cir728. Epub 2011 Nov 4.

13.

Polymorphic mutations associated with the emergence of the multinucleoside/tide resistance mutations 69 insertion and Q151M.

Scherrer AU, von Wyl V, Götte M, Klimkait T, Cellerai C, Yerly S, Böni J, Held L, Ledergerber B, Günthard HF; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):105-12. doi: 10.1097/QAI.0b013e31823c8b69.

PMID:
22027876
14.

Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors.

Cellerai C, Harari A, Stauss H, Yerly S, Geretti AM, Carroll A, Yee T, Ainsworth J, Williams I, Sweeney J, Freedman A, Johnson M, Pantaleo G, Kinloch-de Loes S.

PLoS One. 2011 Apr 5;6(4):e18164. doi: 10.1371/journal.pone.0018164.

15.

Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7R{alpha} (CD127) and perforin expression.

Cellerai C, Perreau M, Rozot V, Bellutti Enders F, Pantaleo G, Harari A.

J Virol. 2010 Apr;84(8):3868-78. doi: 10.1128/JVI.02565-09. Epub 2010 Feb 3.

16.

Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure.

Harari A, Bellutti Enders F, Cellerai C, Bart PA, Pantaleo G.

J Virol. 2009 Apr;83(7):2862-71. doi: 10.1128/JVI.02528-08. Epub 2009 Jan 28.

17.

EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone.

McCormack S, Stöhr W, Barber T, Bart PA, Harari A, Moog C, Ciuffreda D, Cellerai C, Cowen M, Gamboni R, Burnet S, Legg K, Brodnicki E, Wolf H, Wagner R, Heeney J, Frachette MJ, Tartaglia J, Babiker A, Pantaleo G, Weber J.

Vaccine. 2008 Jun 13;26(25):3162-74. doi: 10.1016/j.vaccine.2008.02.072. Epub 2008 May 6.

PMID:
18502003
18.

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.

Harari A, Bart PA, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl JP, Esteban M, Heeney J, Frachette MJ, Tartaglia J, McCormack S, Babiker A, Weber J, Pantaleo G.

J Exp Med. 2008 Jan 21;205(1):63-77. doi: 10.1084/jem.20071331. Epub 2008 Jan 14.

19.

Treatment of acute HIV-1 infection: are we getting there?

Cellerai C, Little SJ, Loes SK.

Curr Opin HIV AIDS. 2008 Jan;3(1):67-74. doi: 10.1097/COH.0b013e3282f31d4b.

PMID:
19372946
20.

Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype.

Harari A, Cellerai C, Bellutti Enders F, Köstler J, Codarri L, Tapia G, Boyman O, Castro E, Gaudieri S, James I, John M, Wagner R, Mallal S, Pantaleo G.

Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16233-8. Epub 2007 Oct 2.

21.

Functional and phenotypic characterization of tetanus toxoid-specific human CD4+ T cells following re-immunization.

Cellerai C, Harari A, Vallelian F, Boyman O, Pantaleo G.

Eur J Immunol. 2007 Apr;37(4):1129-38.

22.

Functional signatures of protective antiviral T-cell immunity in human virus infections.

Harari A, Dutoit V, Cellerai C, Bart PA, Du Pasquier RA, Pantaleo G.

Immunol Rev. 2006 Jun;211:236-54. Review.

PMID:
16824132
23.

Role of HIV-1-specific CD4 T cells.

Harari A, Cellerai C, Pantaleo G.

Curr Opin HIV AIDS. 2006 Jan;1(1):22-7. doi: 10.1097/01.COH.0000194103.28063.35.

PMID:
19372779
24.

HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells.

Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, Pantaleo G.

Proc Natl Acad Sci U S A. 2005 May 17;102(20):7239-44. Epub 2005 May 4.

Supplemental Content

Loading ...
Support Center